Yhn HealthMental Health first seen 3 d ago, last 12 min ago, peak #1
One-Shot CRISPR Therapies Targeting PCSK9 Reviewed
Original: In-Vivo CRISPR/Base-Editing "One-Shot" Therapies Targeting PCSK9
A new review article examines in-vivo CRISPR and base-editing therapies aimed at PCSK9, the gene that regulates LDL cholesterol. These 'one-shot' treatments are designed to permanently lower cholesterol after a single infusion, potentially replacing daily statins for some patients. Early clinical programs in this area have shown durable cholesterol reductions, and the review consolidates the current state of research and remaining safety questions.
Why now: Permanent cholesterol-lowering gene editing is a major step toward replacing lifelong daily medication, drawing wide interest.
PCSK9CRISPRSpringerLDL cholesterol
Rank over time, top of the chart is #1. 5 snapshots from 5 h ago to 12 min ago.
Evidence
API: https://socialmediatrends-api.osmike.com/v1/trends/3255814